An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease. Southampton ...

UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results from a phase 2 study that started last March.

The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection. The protein is inhaled directly into the lungs ...

It was developed at Southampton University Hospital and is being produced by the Southampton-based biotech company, Synairgen. A course of treatment with the new drug could cost around £2,000 ...

Here's a reminder of the day he first suggested bleach injections and UV light - inside the body :) The most recent information from Synairgen suggests that the trial finance is in place ...

Trading could continue to be subdued in the short term, and share price weakness offers investors an ...

As of 8:01 am GMT+2. Market open. There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

As of 10:56 BST. Market open. There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...